Executive Director, Oncology Access

Overview

The Executive Director, Oncology Access is accountable for orchestrating the overall strategy and positioning Menarini Stemline as a current/future leader in Oncology for the following customer segments/channels in coordination with necessary internal stakeholders (Market Access, Brand teams, Sales, Finance, Operations, etc.).

• Physician Network Groups (e.g. Florida Cancer, Tennessee Oncology)
• Priority IDNs and Health Systems
• Oncology State Societies

Responsibilities

Team Leadership

• Lead, develop and motivate a team of customer facing Oncology Access Directors who are accountable for removing clinical, financial, and operational barriers across physician network groups and target national provider accounts (Academic and Community), including precision medicine and reimbursement opportunities/challenges.
• Manage performance and address skill development for direct reports to ensure appropriate business management.
• Develop and maintain strong working relationships with C-Suite and influential leaders in senior management with a goal of understanding unique business needs and strategic challenges of the customers.
• Partner with internal cross functional partners to appropriately achieve business objectives and resolve account related issues.
• Represent Stemline at key conferences and vendor functions, which impact relationships with key customers

Provider Access Strategy

• Lead strategic planning exercises to inform the long-term Stemline provider access strategy including presentations and alignment with executive leadership
• Ensure that appropriate performance metrics are included in strategic account plans and are being reported across the organization.
• Maintain a deep understanding of the Community Oncology and Health System Oncology landscape
• When account specific issues and challenges are identified, engage with appropriate internal resources to assist.
• As needed, present business cases for opportunities/evaluation including a broad view of the enterprise impact.
• Inform dispensing and distribution strategies with insights from customers.

Performance Management

• Set clear performance objectives/expectations and provide ongoing coaching and development of direct reports including concrete business objectives.
• Create KPIs that measure success and align with Stemline business objectives.
• Continuously review, evaluate and recommend improvements to organization to enable higher performance.
• Manage field team expenses according to budget.
• Ensure all field team activities are conducted compliantly.

Qualifications

• Bachelor's degree required, advanced business or science degree desirable.
• 15+ years in Pharmaceutical Industry
• Minimum 8 years work experience within various areas of Market Access OR extensive experience and success leading teams in a matrixed organization
• Demonstrated success in finding the point of intersection between customer and business priorities
• Thorough understanding of market dynamics across multiple therapeutic areas (Oncology/Hematology preferred) and across various business segments
• Ability to develop and maintain strong business partnerships with C-Suite and influence leaders in senior management within key provider accounts.
• Understanding of the entire account segment/channels including payor, trade distribution network, and specialty pharmacy providers.
• Team player and self-starter with a constructive attitude.
• Must have a "roll-up their sleeves" work style understanding both tactical and strategic work requirements
• Overnight travel of 30% may be required.

Preferred:

• Demonstrated success in Oncology strategic account management as an individual contributor and/or leading account management teams.

Base Salary Range of $279,000 to $358,000. Menarini Stemline offers generous compensation and benefits packages, including Short and Long-Term Incentive Programs, Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.


Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group's headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini's oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company's development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business.